| |
|
|
|
Trillium Therapeutics Inc.  
|
|
6 0.05 (0.01%) |
09-21 15:59 |
|
Open: |
6.05 |
Pre close: |
5.95 |
Target:
|
7.88
|
|
High: |
6.0718 |
Low: |
5.95 |
Resistance:
|
6.75
7.88
|
|
Volume: |
48,196 |
Market Cap: |
87M |
Support:
|
5.70
5.05
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
6.12
 |
MACD |
MACD(12,26):
|
0.17 |
|
MA(20): |
6.01  |
Signal(12,26,9): |
0.20 |
|
MA(100): |
5.83 |
Stochastic Oscillator |
%K(14,3):
|
30.11 |
|
MA(250): |
6.95 |
%D(3): |
42.44 |
|
Average Volume(K) |
3-Month: |
6668
|
52-Week |
High:
|
13.30 |
|
10-Days: |
9429 |
Low: |
4.80 |
|
RSI |
RSI(14):
|
53.23 |
Change(%): |
18.8 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.780 |
Return on Equity (ttm) |
-256.2 |
Shares Out. (M) |
14.42 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
-52.3 |
Shares Float (M) |
14.42 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
40.10 |
|
Forward EPS |
-2.917 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
113 |
|
Book Value (p.s.) |
11.470 |
EBITDA (p.s.) |
-0.567 |
P/E |
-2.16 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.52 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-24.74 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-14.40 |
P/CF |
-3.50 |
|
|
|
|
|
|
